[
    [
        {
            "time": "",
            "orginal_text": "医药生物行业周报：板块持续回调 逢低布局景气度高的细分赛道",
            "features": {
                "keywords": [
                    "医药生物",
                    "板块回调",
                    "逢低布局",
                    "景气度高",
                    "细分赛道"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "医药生物行业周报：板块持续回调 逢低布局景气度高的细分赛道",
            "scores": {
                "News_content": "医药生物行业周报：板块持续回调 逢低布局景气度高的细分赛道",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 4,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "【异动股】药明康德(02359-HK)跌3.09%",
            "features": {
                "keywords": [
                    "药明康德",
                    "股价下跌",
                    "异动股"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "【异动股】药明康德(02359-HK)跌3.09%",
            "scores": {
                "News_content": "【异动股】药明康德(02359-HK)跌3.09%",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "orginal_text": "创新药行业周报：贝达药业ALK抑制剂恩沙替尼获批",
            "features": {
                "keywords": [
                    "创新药",
                    "贝达药业",
                    "恩沙替尼",
                    "获批"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "创新药行业周报：贝达药业ALK抑制剂恩沙替尼获批",
            "scores": {
                "News_content": "创新药行业周报：贝达药业ALK抑制剂恩沙替尼获批",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 7,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "医药生物行业周报：医保谈判进入关键阶段 创新药可及性进一步提升",
            "features": {
                "keywords": [
                    "医药生物",
                    "医保谈判",
                    "创新药",
                    "可及性提升"
                ],
                "sentiment_score": 0.6,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药生物"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "original_text": "医药生物行业周报：医保谈判进入关键阶段 创新药可及性进一步提升",
            "scores": {
                "News_content": "医药生物行业周报：医保谈判进入关键阶段 创新药可及性进一步提升",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "orginal_text": "医药股再度走弱，石药集团跌超5%",
            "features": {
                "keywords": [
                    "医药股",
                    "走弱",
                    "石药集团",
                    "股价下跌"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "original_text": "医药股再度走弱，石药集团跌超5%",
            "scores": {
                "News_content": "医药股再度走弱，石药集团跌超5%",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 8,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "orginal_text": "新兴品牌突围战：知识产权才是最后的“生死线”",
            "features": {
                "keywords": [
                    "新兴品牌",
                    "知识产权",
                    "生死线"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "original_text": "新兴品牌突围战：知识产权才是最后的“生死线”",
            "scores": {
                "News_content": "新兴品牌突围战：知识产权才是最后的“生死线”",
                "Correlation": 5,
                "Sentiment": 5,
                "Importance": 6,
                "Impact": 5,
                "Duration": 6,
                "Entity_Density": 3,
                "Market_Scope": 7,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        }
    ]
]